Monoclonal antibodies have ushered in a new era of MM immunotherapy, with the most successful being Daratumumab and Isatuximab, which target CD38,4,5 and Elotuzumab, which targets SLAMF7 located on myeloma cells and natural killer cells.6 The utilization of these medications has revolutionized the MM treatment paradigm from conventional chemotherapy to a more personalized, precision medicine. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.